

26. El-Zaatari Z, Divatia MK. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma: Morphological appraisal with a comprehensive review of differential diagnoses. *Indian J Pathol Microbiol.* 2020; 63(Supplement): S7–17.
27. Kuroda N, Tsutsui M, Iguchi M, et al. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms. *Ann Diagn Pathol.* 2020; 49: 151599.
28. Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. *Mod Pathol.* 2015; 28(6): 845–853.
29. Wang Y, Zhao P, Wang L, et al. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma. *Pathol Res Pract.* 2022; 235: 153960.
30. Shah RB, Stohr BA, Tu ZJ, et al. „Renal Cell Carcinoma With Leiomyomatous Stroma” Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity. *Am J Surg Pathol.* 2020; 44(5): 571–581.
31. Iannantuono GM, Riordino S, Sganga S, Roselli M, Torino F. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. *Int J Mol Sci.* 2022; 23(7): 3995.
32. Pal SK, Bergerot P, Dizman N, et al. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. *Eur Urol.* 2018; 74(1): 124–128.
33. Calderaro J, Moroch J, Pierron G, et al. SMARCB1/INI1 inactivation in renal medullary carcinoma. *Histopathology.* 2012; 61(3): 428–435.